WHO ICTRP trial
Phase 2, Open-label, Long-term study of the safety and efficacy of TM5614 in…
JPRN-jRCT2031190071 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031190071 |
|---|---|
| Public title | Phase 2, Open-label, Long-term study of the safety and efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patients |
| Scientific title | Phase 2, Open-label, Long-term study of the safety and efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patients |
| Primary sponsor | Harigae Hideo |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Chronic myelogenous leukemia in chronic phase CML;D015464 |
| Interventions | TM5614 (150mg, once a day after breakfast orally for 48 weeks);D000284 |
| Registration date | Aug 8, 2019 |
| Target size | 35 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: